Anales de la RANM

134 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 HIPOTENSIÓN EN HIPERTENSOS MAYORES TRATADOS Banegas JR An RANM. 2022;139(02): 128 - 134 28. Evans JG, Rose G. Br Med Bull. 1971;27(1):37- 42. Hypertension. doi: 10.1093/oxfordjour- nals.bmb.a070812. 29. Sánchez-Martínez M, López-García E, Gua- llar-Castillón P, et al. Home and ambulatory blood pressure levels below target range and clinical effort to detect this condition: a po- pulation-based study in older treated hyper- tensives. Age Ageing. 2022;51(2):afab236. doi: 10.1093/ageing/afab236. 30. Gutiérrez-Misis A, Sánchez-Santos MT, Banegas JR, et al. Walking speed and high blood pressure mortality risk in a Spanish elderly population. 31. J Hum Hypertens. 2015;29(9):566-572. doi: 10.1038/jhh.2015.32. 32. Umemura S, Arima H, Arima S, et al. The Japanese Society of Hypertension Guideli- nes for the Management of Hypertension (JSH 2019). Hypertension Research (2019) 42:1235-1481. https://doi.org/10.1038/ s41440-019-0284-9 33. Spence JD, Müller LO, Blanco PJ. How to iden- tify which patients should not have a systo- lic blood pressure target of <120 mmHg. Eur Heart J. 2022;43(6):538-539. doi: 10.1093/eu- rheartj/ehab552. 34. Verwoert GC, Mattace-Raso FU, Hofman A, et al. Orthostatic hypotension and risk of cardio- vascular disease in elderly people: the Rotterdam study. J Am Geriatr Soc 2008;56:1816–1820. 35. Argulian E, Grossman E, Messerli FH. Mis- conceptions and facts about treating hyper- tension. Am J Med. 2015;128(5):450-455. doi: 10.1016/j.amjmed.2014.11.015. 36. Lee SSY, Mackey DA. Glaucoma – risk factors and current challenges in the diagnosis of a leading cause of visual impairment. Maturi- tas 2022;163:15–22. doi.org/10.1016/j.maturi- tas.2022.05.002 37. Messerli FH, Streit S, Grodzicki T. The oldest old: does hypertension become essential again? 38. Eur Heart J. 2018;39(33):3144-3146. doi: 10.1093/eurheartj/ehy525. 39. Messerli FH, Brguljan J, Rexhaj E, Sever P, Pocock S, Taddei S. Lowering systolic blood pressure to 120 mmHg or The Lancet's true grit. Eur Heart J. 2021;42(21):2052-2059. doi: 10.1093/eurheartj/ehab013. 40. Ou YN, Tan CC, Shen XN, Xu W, Hou XH, Dong Q, Tan L, Yu JT. Blood Pressure and Risks of Cognitive Impairment and Demen- tia: A Systematic Review and Meta-Analysis of 209 Prospective Studies. Hypertension. 2020;76(1):217-225. doi: 10.1161/HYPERTEN- SIONAHA.120.14993. Epub 2020 May 26. 41. Zhang ZY, Yu YL, Asayama K, Hansen TW, Maestre GE, Staessen JA. Starting Antihy- pertensive Drug Treatment With Combina- tion Therapy: Controversies in Hypertension - Con Side of the Argument. Hypertension. 2021;77(3):788-798. doi: 10.1161/HYPER- TENSIONAHA.120.12858. 42. Gorostidi M, Banegas JR, Sierra A, et al. Ambulator y blood pressure monitoring in daily clinical practice. The Spanish ABPM Registr y experience. Eur J Clin Invest 2016;46:92-98. 43. Martín-Rioboó E, Pérula de Torres LA, Banegas JR, et al; MAMPA, PAPPS Study Groups. Knowledge, availability, and use of ambulatory and home blood pressure moni- toring in primary care in Spain: the MAMPA study. J Hypertens. 2018;36(5):1051-1058. doi: 10.1097/HJH.0000000000001673. 44. Nilsson PM, Boutouyrie P, Laurent S. Vascular aging: A tale of EVA and ADAM in cardiovas- cular risk assessment and prevention. Hyper- tension 2009;54:3-10. DECLARACIÓN DE TRANSPARENCIA El autor/a de este artículo declara no tener ningún tipo de conflicto de intereses respecto a lo expuesto en el presente trabajo. Si desea citar nuestro artículo: Banegas JR. Hipotensión en hipertensos mayores tratados. Carga epidemiológica y eficiencia de su detección. An RANM. 2022;139(02): 121– 134. DOI: 10.32440/ar.2022.139.02. rev02